TheScreener - Egyptian International Pharmaceutical Ind (PHAR) EGYPT INTL PHARMACEU sees an upgrade to Positive due to a better fundamental star rating

Report

TheScreener

EUR 12.83 For Business Accounts Only

EGYPT INTL PHARMACEU sees an upgrade to Positive due to a better fundamental star rating

The general evaluation of EGYPT INTL PHARMACEU (EG), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Positive. As of the analysis date March 22, 2022, the closing price was EGP 40.61 and its potential was estimated at EGP 43.84.

23/03/2022 1 EN

Underlying

Egyptian International Pharmaceutical Ind

Co. is principally engaged in the manufacture and distribution of pharmaceutical products locally and for export. Co. currently has 196 products including analgesic, anthelmintics, antibiotics, anticatarrhal, antidepressant, antidysentrics & enterostatics, antihistaminic, cardiasc and vascularetics, cathartics, dermatological, endocrine system drugs, gastrointestinal, general anaesthetic, glucocorticoid, ophthalmic, orodentals, parasympathomimetic, pulmonics, skeletal muscle relaxants, spasmolytics, treatment of grout, urologic, vaginetics, vitamins and miscellaneous.

See profile

EGS38081C013 Egyptian Exchange Egypt

Provider

TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.

See profile

Other Reports on these Companies

Tellimer

EIPICO: 1Q23: Healthy Annually, Hindered Sequentially; Adjust FV to EGP35.00

ASP SOLELY DRIVES PHARMA MARKET GROWTH The pharma market has been significantly challenged since 2020 (covid outbreak), before starting to gradually show signs of recovery in 1Q22. However, the Russian Invasion of Ukraine along with the rounds of EGP depreciation have capped growth and slowed down the recovery. The Egyptian pharma market has always been price-driven, where price increases used to drive two-thirds of the growth. However, given the current challenging macro dynamics (including ...

PREMIUM

May 25, 2023 May 25, 2023 1 EN

Tellimer

EIPICO: 4Q22 | Healthy revenues and FX gains shape bottom-line

ASP SOLELY DRIVES PHARMA MARKET GROWTH Pharma market has been significantly challenged since 2020 (covid outbreak), before starting to gradually show signs of recovery in 1Q22. However, the Russian Invasion of Ukraine along with the rounds of EGP depreciation have capped growth and slowed down the recovery. The Egyptian pharma market has always been price-driven, where price increases used to drive two thirds of the growth. However, given the current challenging macro dynamics (including EGP ...

PREMIUM

March 2, 2023 March 2, 2023 1 EN

Tellimer

EIPICO: Healthy annual performance, stable sequentially

RETAIL PHARMA MARKET CONFIRMED SIGNS OF RECOVERY IN 1Q22 Retail pharma has partially recovered in 2021, confirming the sustainability of the gradual sequential recovery expected in 2022. According to IQVIA, retail pharma sales recorded EGP86.45 billion in 2021, showing a modest of 7% YoY, according to the latest available data. Such YoY growth is higher than 2020 retail pharma market growth (+4% YoY growth) but is still below 2019 double-digit growth levels of c.17% YoY. In 1Q22, retail pharm...

PREMIUM

May 25, 2022 May 25, 2022 1 EN

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

AC ENERGY CORP (PH), a company active in the Alternative Electricity industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 4 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date April 8, 2022, the closing price was PHP 8.54 and its expected value was estimated at PHP 8.53.

Free Trial

April 9, 2022 April 9, 2022 1 EN

With a more favourable environment, VUKILE PROPERTY improves to Positive

VUKILE PROPERTY (ZA), a company active in the Real Estate Holding & Development industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date April 5, 2022, the closing price was ZAR 13.72 and its potential was estimated at ZAR 15.16.

Free Trial

April 6, 2022 April 6, 2022 1 EN

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of ROYAL BAFOKENG PLATINUM (ZA), active in the Platinum & Precious Metals industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date April 5, 2022, the closing price was ZAR 159.78 and its target price was estimated at ZAR 127.50.

Free Trial

April 6, 2022 April 6, 2022 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

EGYPT INTL PHARMACEU sees an upgrade to Positive due to a better fundamental star rating

Empowering Investors

EIPICO: 1Q23: Healthy Annually, Hindered Sequentially; Adjust FV to EGP35.00

EIPICO: 4Q22 | Healthy revenues and FX gains shape bottom-line

EIPICO: Healthy annual performance, stable sequentially

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

With a more favourable environment, VUKILE PROPERTY improves to Positive

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe